Glutamate a big target for drug developers
The New York Times' Alex Berenson looks at the wave of new research programs focused on the neurotransmitter glutamate as a therapy for schizophrenia. Eli Lilly's Darryle D. Schoepp recognized its potential in the fall of 2006, and other drug discoverers weren't far behind as a number of developers jumped into the field. All approved therapies for schizophrenia target dopamine, and the glutamate connection opened up a host of possibilities for depression, Alzheimer's and other indications as well.
"I don't think people appreciate how much money, time and good technical research goes into what we do," Schoepp told the Times. "Sometimes, people think the idea is the thing. I think the idea can be the easy part."
- read the article from The New York Times
Related Articles:
Potential new drug found for schizophrenia. Report
Addex is talking deals as interest in a new class of drugs. Profile
Comments (1) | Post a comment
Comments
By Anonymous | Posted 10:44am | February 27, 2008
Schoepp has been working on glutamate for over 20 years and thus recognized its potential long before the "fall of 2006". Also, Schoepp now works for Merck & Co., Inc.
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets